Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Scott

Showing results (11-20 of 80) with videos related to

Pageof 8
Sort By:
Transfusion|January 27, 1999
Hypotensive reactions during transfusion: is bradykinin the culprit?R W Colman, C F Scott
Clinical and Experimental Immunology|July 1, 1983
Lymphocytotoxic antibody in multiple sclerosis: activity against T cell subsets and correlation with disease activityC F Scott, L E Spitler
The Journal of Clinical Investigation|February 1, 1980
Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasmaC F Scott, R W Colman
Blood|March 1, 1996
When and where is factor XI activated by thrombin?R W Colman, C F Scott
Blood|February 1, 1987
Lack of effect of heparin on factor XIaR W Colman, C F Scott
Journal of Immunopharmacology|January 1, 1982
Experimental allergic encephalitis; treatment with drugs which alter CNS serotonin levelsC F Scott, N Cashman, L E Spitler
Blood|October 1, 1982
Effect of heparin on the inactivation rate of human factor XIa by antithrombin-IIIC F Scott, M Schapira, R W Colman
Transactions of the Association of American Physicians|January 1, 1981
High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitorsM Schapira, C F Scott, R W Colman
The Journal of Clinical Investigation|February 1, 1982
Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasmaM Schapira, C F Scott, R W Colman
Annals of the New York Academy of Sciences|January 1, 1981
Regulation of the formation and inhibition of human plasma kallikreinR W Colman, M Schapira, C F Scott
Pageof 8

Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Transfusion|January 27, 1999
Hypotensive reactions during transfusion: is bradykinin the culprit?R W Colman, C F Scott
Clinical and Experimental Immunology|July 1, 1983
Lymphocytotoxic antibody in multiple sclerosis: activity against T cell subsets and correlation with disease activityC F Scott, L E Spitler
The Journal of Clinical Investigation|February 1, 1980
Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasmaC F Scott, R W Colman
Blood|March 1, 1996
When and where is factor XI activated by thrombin?R W Colman, C F Scott
Blood|February 1, 1987
Lack of effect of heparin on factor XIaR W Colman, C F Scott
Journal of Immunopharmacology|January 1, 1982
Experimental allergic encephalitis; treatment with drugs which alter CNS serotonin levelsC F Scott, N Cashman, L E Spitler
Blood|October 1, 1982
Effect of heparin on the inactivation rate of human factor XIa by antithrombin-IIIC F Scott, M Schapira, R W Colman
Transactions of the Association of American Physicians|January 1, 1981
High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitorsM Schapira, C F Scott, R W Colman
The Journal of Clinical Investigation|February 1, 1982
Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasmaM Schapira, C F Scott, R W Colman
Annals of the New York Academy of Sciences|January 1, 1981
Regulation of the formation and inhibition of human plasma kallikreinR W Colman, M Schapira, C F Scott
Pageof 8